Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : allo-APZ2-OTS
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Recipient : RHEACELL
Deal Size : Undisclosed
Deal Type : Agreement
Rheacell and AOP Health Partner to Commercialize Cell Therapies in Europe
Details : Under the agreement, AOP will commercialize Rheacell’s two stem cell products, Ebesanar and Amesanar, in Europe, Turkey, Israel and the MENA region.
Product Name : Ebesanar
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 27, 2025
Lead Product(s) : allo-APZ2-OTS
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Recipient : RHEACELL
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : allo-APZ2-CVU
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : RHEACELL
Deal Size : Undisclosed
Deal Type : Partnership
Rheacell and AOP Health Unite for Butterfly Disease and Venous Wound Therapy
Details : The partnership aims to develop and deliver innovative cell therapies, Ebesanar and Amesanar for patients suffering from Butterfly Children’s Disease and Chronic Venous Wounds.
Product Name : Amesanar
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 27, 2025
Lead Product(s) : allo-APZ2-CVU
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : RHEACELL
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Landiolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Approves AOP Health’s Rapiblyk™ for Atrial Fibrillation and Flutter
Details : Rapiblyk (landiolol) is a β1-adrenergic receptor antagonist, small molecule drug candidate which is indicated for the treatment of supraventricular tachycardia.
Product Name : Rapiblyk
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2024
Lead Product(s) : Landiolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BESREMi (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon. It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi is designed to be self-administered subcutaneously...
Product Name : Besremi
Product Type : Protein
Upfront Cash : Inapplicable
December 13, 2022
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BESREMi (Ropeginterferon alfa-2b) is long-acting, mono-pegylated proline interferon, unique pharmacokinetic properties new level of tolerability, designed to be conveniently self-administered subcutaneously with pen once every two weeks, or up to monthly...
Product Name : Besremi
Product Type : Protein
Upfront Cash : Inapplicable
June 13, 2022
Lead Product(s) : Ropeginterferon-Alpha-2B
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable